Jiexin Medical Technology (Ningbo) Co., Ltd., founded in January 2024, is a specialist in the cardiovascular intervention market, with a particular emphasis on cardiac electrophysiology. The company has engineered a comprehensive product system that encompasses every link in the process, from channel establishment and mapping to ablation and cardioversion. Notably, its atrial septal puncture system and balloon mapping catheter have already received market approval. Recently, Jiexin Medical proudly announced the successful completion of an Angel+ round of financing, raising tens of millions of yuan. This round was spearheaded by Chengshu Investment, with additional support from Sanjiang Capital and Qianrong Holdings. The newly acquired funds will be strategically allocated towards factory construction, market promotion efforts, and the development of innovative new products.

Atrial septal puncture stands as a pivotal step in left heart intervention procedures. However, traditional devices have been plagued by several limitations. Jiexin Medical's atrial septal puncture system addresses these issues head-on, enhancing both the safety and efficiency of the puncture process through five groundbreaking structural innovations. Furthermore, its disposable balloon mapping catheter is meticulously designed for use in the Marshall vein and other small vessels, effectively overcoming multiple challenges associated with traditional procedures.

Looking ahead, Jiexin Medical has a robust pipeline of products in the works, covering a wide range of areas such as cardioversion and mapping. The company is led by founder Gong Jie, who brings nearly two decades of experience in medical device R&D and operations to the table. Co-founder Zhang Dongkui, on the other hand, boasts nearly 20 years of sales management expertise in the medical field. Chengshu Investment, Sanjiang Capital, Qianrong Holdings, and existing shareholder Daoyuan Capital have all voiced their approval of Jiexin Medical's team and products, expressing confidence in the company's bright future.